摘要
目的探讨布地奈德福莫特罗粉吸入剂单用及联合孟鲁司特钠对咳嗽变异性哮喘患者肺功能及预后的影响。方法纳入2019年1月至2020年6月浙江省义乌市中心医院收治的60例咳嗽变异性哮喘患者,采用随机数字表法均分为观察组和对照组,每组30例。观察组采用布地奈德福莫特罗粉吸入剂联合孟鲁司特钠治疗,对照组仅采用布地奈德福莫特罗粉吸入剂治疗。比较两组治疗8周后的临床疗效,治疗前及治疗8周后的咳嗽积分、肺功能指标(呼吸流量峰值、用力肺活量、第1秒用力呼气容积)、嗜酸性粒细胞阳离子蛋白、白细胞介素-5及生活质量(中文版莱斯特咳嗽量表评分),以及不良反应发生情况。结果治疗8周后,观察组临床控制率为96.67%,明显高于对照组的76.67%,差异有显著性(P<0.05)。治疗8周后,两组日间及夜间咳嗽积分、嗜酸性粒细胞阳离子蛋白、白细胞介素-5水平均低于治疗前,且观察组低于对照组,差异有显著性(P<0.05),肺功能指标(呼吸流量峰值、用力肺活量、第1秒用力呼气容积)、中文版莱斯特咳嗽量表评分水平高于治疗前,且观察组高于对照组,差异有显著性(P<0.05)。两组患者不良反应发生率比较差异无显著性(P>0.05)。结论布地奈德福莫特罗粉吸入剂联合孟鲁司特钠治疗咳嗽变异性哮喘疗效良好,可改善患者的肺功能及预后。
Objective To study the effect of budesonide formoterol powder inhalation alone or combined with montelukast sodium on lung function and prognosis of patients with cough variant asthma(CVA).Method 60 patients with CVA treated in Yiwu Central Hospital were included between January 2019 and June 2020 and were divided into observation group and control group according to the random number table method,with 30 cases in each group.The observation group was given budesonide formoterol powder inhalation combined with montelukast sodium,and the control group received budesonide formoterol powder inhalation treatment.The clinical efficacy after 8 weeks of treatment,and cough score,lung function indicators[peak expiratory flow(PEF),forced vital capacity(FVC),forced expiratory volume in the first second(FEV1)],eosinophil cationic protein(ECP),interleukin-5(IL-5)and quality of life[Leicester Cough Questionnaire in Mandarin-Chinese(LCQ-MC)]before treatment and after 8 weeks of treatment were compared between the two groups,and the occurrence of adverse reactions were compared.Result After 8 weeks of treatment,the clinical control rate of 96.67%(29/30)in observation group was significantly higher than 76.67%(23/30)in control group(P>0.05).After 8 weeks of treatment,the scores of day cough and night cough and levels of ECP and IL-5 of the two groups were lower than those before treatment,and the scores and levels of observation group were lower than those of control group.The lung function(PEF,FVC,FEV1)and LCQ-MC scores in the two groups were significantly higher than those before treatment,and the indicators of observation group were higher than those of control group(P<0.05).There were no significant differences in the incidence rates of adverse reactions between the two groups of children patients(P>0.05).Conclusion Budesonide formoterol powder inhalation combined with montelukast sodium has a good efficacy in the treatment of CVA,and it can improve the lung function and prognosis of patients.
作者
周建
迟春天
Zhou Jian;Chi Chuntian(Department of Respiratory Medicine,Yiwu Central Hospital,Zhejiang Yiwu 322000,China)
出处
《中国医刊》
CAS
2021年第11期1200-1203,共4页
Chinese Journal of Medicine
基金
浙江省医药卫生科技计划项目(2017KY690)。
